LENZ Therapeutics Secures Exclusive VIZZ Commercialization Deal in Australia, New Zealand
LENZ is trading near its 52-week low of $5.73 (3.2% above the low).
Summary
LENZ Therapeutics announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals for its VIZZ product in Australia and New Zealand. The deal includes an upfront payment and a significant profit share from product sales. This marks LENZ's fifth international partnership for VIZZ, following a similar deal with Everest Medicines announced on June 7th. The expansion into new markets is crucial for the company, which reported increased Q1 losses due to VIZZ commercialization investments, as it contributes to future revenue and offsets commercialization costs.
At the time of this announcement, LENZ was trading at $5.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $180.3M. The 52-week trading range was $5.73 to $50.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.